Serotonin reuptake inhibitor withdrawal

Journal of Clinical Psychopharmacology

Volumn 16, Issue 5, 1996, Pages 356-362

  Coupland, Nick J ^a,c   Bell, Caroline J ^b   Potokar, John P ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; DREAM; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; VERTIGO; WITHDRAWAL SYNDROME;

1-NAPHTHYLAMINE; ADOLESCENT; ADULT; AGE FACTORS; CLOMIPRAMINE; DIZZINESS; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; PARESTHESIA; PAROXETINE; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SEX FACTORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0029802675     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199610000-00003     Document Type: Article

References (33)

1. American Psychiatric Association. Practice guidelines for major depressive disorder in adults. Am J Psychiatry 1993;159[suppl]: 1-26.
2. Schweizer E, Rickels K, Uhlenhuth EF. Issues in the long-term treatment of anxiety disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1349-59.
3. Montgomery SA. Pharmacological treatment of obsessive compulsive disorder. In: Hollander E, Zohar J, Marazzati D, Olivier B, editors. Current insights in obsessive compulsive disorder. Chichester, England: John Wiley & Sons Ltd., 1994:215-25.
4. Dilsalver SC. Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf 1994;10:103-14.
5. Cooper GL. The safety of fluoxetine - an update. Br J Psychiatry 1988;153[suppl 3]:77-86.
6. Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiatry 1991;148:1263.
7. Szabadi E. Fluvoxamine withdrawal syndrome. Br J Psychiatry 1992;160:283-4.
8. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry 1994;151:289.
9. Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993;54:146-9.
10. Committee on Safety of Medicines. Current Problems in Pharmacovigilance 1993;19:1.
11. Mallya G, White K, Gunderson C. Is there a serotonergic withdrawal syndrome? Biol Psychiatry 1993;33:851-2.
12. Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 1994;14:206-7.
13. Louie AK, Lannon RA, Ajari LJ. Withdrawal reaction after sertraline discontinuation. Am J Psychiatry 1994;151:450-1.
14. Debattista C, Schatzberg AF. Physical symptoms associated with paroxetine withdrawal. Am J Psychiatry 1995;152:1235-6.
15. Einbinder E. Fluoxetine withdrawal? Am J Psychiatry 1995;152: 1235.
16. Frost L, Lal S. Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors. Am J Psychiatry 1995;152: 810.
17. Koopowitz LF, Berk M. Paroxetine induced withdrawal effects. Hum Psychopharmacol 1995;10:147-8.
18. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Manniche PM. Paroxetine in the treatment of panic disorder. Br J Psychiatry 1995;167:374-97.
19. Pyke RE. Paroxetine withdrawal syndrome. Am J Psychiatry 1995;152:149-50.
20. Lader M. Benzodiazepine withdrawal states. In: Trimble MR, editor. Benzodiazepines divided. New York: John Wiley, 1983:17-31.
21. Pecknold J. The assessment of anxiety and benzodiazepine dependence. In: Hallstrom C, editor. Benzodiazepine dependence. Oxford, England: Oxford University Press, 1993:143-61.
22. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-20.
23. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984;230:94-102.
24. Cusack BM, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994;114:559-65.
25. Wilson SJ, Bell C, Coupland NJ, Nutt DJ. Sleep in depressed out-patients during treatment with fluvoxamine - a home-based study. Eur Neuropsychopharmacol 1995;5:303.
26. Van Bemmel AL, van den Hoofdakker RH, Beersman DGM, Buhuys AL. Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram. Psychopharmacology 1993;113:225-30.
27. Jacobs BL, Fornal CA. 5HT and motor control: a hypothesis. Trends Neurosci 1993;16:346-52.
28. Waterhouse BD, Azizi SA, Burne RA, Woodward DJ. Modulation of rat cortical area 17 neuronal responses to moving visual stimuli during norepinephrine and serotonin microiontophoresis. Brain Res 1990;514:276-92.
29. Watt DGD, Bouyer LJG, Nevo IT, Smith AV, Tiande Y. What is motion sickness? Ann N Y Acad Sci 1992;656:660-7.
30. Lucot JB, Crampton GH. 8-OH-DPAT suppresses vomiting in the cat elicited by motion, cisplatin or xylazine. Pharmacol Biochem Behav 1989;33:627-31.
31. 1A receptor agonists in Suncus murinus. Jpn J Pharmacol 1994;64:109-14.
32. Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993;15:243-5.
33. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15: 220-6.